Brief: Evofem Expects Significant Reduction In PHEXXI Manufacturing Cost Through Agreement With Windtree Therapeutics
26/03/2025 12:49
March 26 (Reuters) - Evofem Biosciences Inc EVFM.PK: EVOFEM EXPECTS SIGNIFICANT REDUCTION IN PHEXXI MANUFACTURING COST THROUGH AGREEMENT WITH WINDTREE THERAPEUTICS EVOFEM BIOSCIENCES INC - COST TO MANUFACTURE PHEXXI WILL DECREASE BY 55% - 60% Source text: ID:nPnbPdj8Da Further company coverage: EVFM.PK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Evofem Biosciences
See all newsBrief: Evofem Biosciences Adds Additional Manufacturing Capacity For Phexx To Support Global Growth Strategy
Brief: HUB Cyber Security Expands Into Women's Health With Zero-Cash Acquisition Of Evofem Notes
Evofem Biosciences Q1 sales edge up on higher pricing
Evofem Biosciences Q3 net sales rise
Brief: Evofem Anticipates Approval Of Merger With Aditxt At Upcoming Stockholder Meeting